ABSTRACT
The successful application of boron neutron capture therapy (BNCT) is dependent on the identi™cation and preparation of boron-containing compounds that can be delivered to and retained by the tumor in signi™cant amounts (>15 μg boron/g tumor) (Fairchild and Bond, 1985). Compounds targeted for application in BNCT must either accumulate in the tumor through natural mechanisms or, in the case of compounds that have no natural propensity for the tumor, be delivered to the tumor using a tumor-speci™c delivery modality. In addition to the required tumor boron concentration, the selected compounds should yield in vivo biodistributions with tumor to normal tissue (including blood) ratios of three or higher and be suf™ciently nontoxic (Hawthorne, 1993; Soloway et al., 1998).
